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miodarone or
ronedarone for
trial Fibrillation
oo Early to Know the Winner?*
aul S. Chan, MD, MSC,†
rahmajee K. Nallamothu, MD, MPH,‡§
akan Oral, MD‡
ansas City, Missouri; and Ann Arbor, Michigan
trial fibrillation (AF) is estimated to affect 10 million
atients by 2050 in the U.S. (1) and is associated with
ignificant rates of morbidity and an increased risk of
ortality. Health care costs due to AF are enormous at$2
illion annually. Restoration of sinus rhythm in patients
ith AF has been demonstrated to improve left ventricular
jection fraction, left atrial size, and quality of life both in
atients with congestive heart failure and normal ejection
raction, even when optimal ventricular rate control during
F has been achieved (2–4). Furthermore, many patients
ith AF are troubled by symptoms that persist despite
dequate rate control. Therefore, maintenance of sinus
hythm often is desirable in patients with AF.
See page 1089
In the most recent American College of Cardiology/
merican Heart Association guidelines, an antiarrhythmic
gent is recommended as first-line therapy to maintain sinus
hythm (5). However, the risk of proarrhythmia, only
odest efficacy, and the risk of organ toxicity (amiodarone)
ave complicated antiarrhythmic drug therapy. In a recent
eta-analysis (6), Vaughan-Williams Class 1A antiarrhyth-
ic agents like quinidine and disopyramide were associated
ith a 2-fold increased risk for all-cause mortality when
ompared with placebo, and sotalol was associated with a
trong trend toward a greater risk of mortality. Although
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Mid America Heart Institute and the University of Missouri-Kansas
ity, Kansas City, Missouri; ‡Division of Cardiology, University of Michigan School
f Medicine, Ann Arbor, Michigan; and the §Ann Arbor Veterans Administration
ealth Services Research & Development Center for Excellence, Ann Arbor,a
ichigan. Dr. Oral is a founder of Ablation Frontiers, Inc., and has received research
rants from Boston Scientific, St. Jude Medical, and GlaxoSmithKline.here were insufficient mortality data for Class 1C antiar-
hythmic agents, propafenone and flecainide have been
inked to worse outcomes in patients with ischemic heart
isease or cardiomyopathy (7). Furthermore, a post hoc
nalysis of the AFFIRM (Atrial Fibrillation Follow-up
nvestigation of Rhythm Management) study suggested
hat the beneficial effects of sinus rhythm on survival were
egated by the negative effect of antiarrhythmic drug
herapy on survival (8).
Dofetilide has been recommended as an alternative to
miodarone in patients with a reduced ejection fraction and
an also be considered in patients with coronary artery
isease or for second-line therapy in patients without
tructural heart disease (5). Because of the risk of proar-
hythmia, however, dofetilide requires inpatient initiation of
herapy under electrocardiogram monitoring and only by
ertified providers.
Although amiodarone is associated with organ toxicity, it
ppears to have a lower risk of proarrhythmia than other
gents. Amiodarone has been one of the few and sometimes
s the only agent recommended in patients with structural
eart disease. For example, in patients with substantial left
entricular hypertrophy, it is the only agent recommended
n the American College of Cardiology/American Heart
ssociation guidelines (5). However, to date, only 4 small
andomized trials involving 669 patients have been per-
ormed comparing amiodarone with placebo for patients
ith AF (6). This is one reason why currently approved
ndications by the Food and Drug Administration do not
nclude AF (9). Yet, 2 million prescriptions for amioda-
one are filled annually, with 80% of these related to
ff-label uses like AF (10). Importantly, the use of amioda-
one is not without serious side effects resulting from its
igh iodine content.
For these reasons, there has been great interest in
ronedarone, a novel compound that shares many structural
imilarities with amiodarone but without the iodine. In
ecent trials, dronedarone has generated substantial interest
y demonstrating a reduction in recurrence of AF without
erious side effects (11). In the ATHENA (A Trial With
ronedarone to Prevent Hospitalization or Death in Pa-
ients With Atrial Fibrillation) trial (12), dronedarone was
ound to reduce the rate of the primary end point of
ardiovascular hospitalization and cardiovascular mortality
y 24% (31.9% vs. 39.4%; hazard ratio [HR]: 0.76; 95%
onfidence interval [CI]: 0.69 to 0.84; p  0.001) and of
ardiovascular mortality alone by 29% (2.7% vs. 3.9%; HR:
.71; 95% CI: 0.51 to 0.98; p  0.03). To date, this is the
rst antiarrhythmic treatment of AF that has been shown to
mprove a composite end point of cardiovascular morbidity
nd mortality. However, it should be noted that freedom
rom recurrent AF was not an end point in the ATHENA
rial.
It is with these issues in mind that the indirect meta-
nalysis by Piccini et al. (13) in this issue of the Journal, in
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September 15, 2009:1096–8 Amiodarone or Dronedarone for AFhich they compared amiodarone with dronedarone in AF,
akes on a larger significance. Because adequately powered
linical trials comparing these 2 agents are not available,
ndirect meta-analysis remains the only means of comparing
heir relative effectiveness and safety by extrapolating results
rom individual trials comparing each against placebo. The
uthors found in their meta-analysis that patients treated
ith amiodarone, compared with dronedarone, were twice
s likely to remain in sinus rhythm (for recurrent AF: odds
atio [OR]: 0.49; 95% CI: 0.37 to 0.63; p  0.001).
owever, amiodarone was associated with a trend toward
reater all-cause mortality (OR: 1.61; 95% CI: 0.97 to 2.68;
 0.07) and was associated with greater rates of adverse
vents requiring drug discontinuation (OR: 1.81; 95% CI:
.33 to 2.46; p  0.001).
There are 2 important aspects of this study. First, the
uthors used a novel meta-analytical approach to compare 2
rugs that have not been studied in a head-to-head random-
zed controlled trial. Second, by using this technique, they
ave been able to address the important clinical question
f whether dronedarone should be preferred as initial
herapy over amiodarone in patients with AF who need
n effective but also safe antiarrhythmic agent.
However, given the large number of patients with AF and
he major public health implications, their findings need
o be interpreted carefully and in the proper context.
irst, indirect meta-analysis has significant limitations be-
ond those associated with meta-analyses in general, even
hen applied appropriately as in this study. Results from
ndirect meta-analyses may overestimate the relative effec-
iveness of the compared treatments because of the assump-
ion that there is no interaction between different study
opulations across trials. For example, an indirect meta-
nalysis in which the authors compared sulfamethoxazole/
rimethoprim with dapsone/pyrimethamine found the
ormer to be associated with a 63% reduction (risk ratio:
.37; 95% CI: 0.21 to 0.65) in Pneumocystis carinii pneumo-
ia but with a more modest 36% reduction (risk ratio: 0.64;
5% CI: 0.45 to 0.90) during direct meta-analysis because of
he different types of patients studied across these trials (14).
t is noteworthy that all 4 dronedarone studies excluded
atients with permanent AF, whereas 2 of the 4 amiodarone
tudies excluded patients with paroxysmal AF. Differences
n study populations and treatments (as was observed with
arfarin use) between these trials could lead to biased
stimates with indirect meta-analysis. It is likely that ami-
darone studies were more likely to include patients with
tructural heart disease and also persistent/permanent forms
f AF.
Second, it is noteworthy that there were almost 9 times
s many patients in the trials evaluating dronedarone
n  5,967) than in those evaluating amiodarone (n 
69), largely because of the ATHENA trial. Sensitivity
nalyses were not performed (specifically with the
THENA trial for dronedarone), which would have
een helpful, especially given several of the marginal andings. In addition, the authors could have considered
ncluding patients from other AF trials such as AFFIRM
15), in sensitivity analyses for amiodarone, because
miodarone was used in the majority of these patients. If
nclusion of the AFFIRM trial attenuated the relative
ortality risk for amiodarone, additional caution would
e needed in interpreting the mortality estimates from
his indirect meta-analysis.
Third, although the authors of this study were primarily
nterested in examining the effect of these drugs in AF, it
emains a concern that dronedarone has been shown to
esult in a 2-fold increased mortality risk in patients with
eft ventricular systolic dysfunction (3.8% vs. 8.1%; HR:
.13; 95% CI: 1.07 to 4.25; p  0.03) (16). The presence of
eft ventricular systolic dysfunction is common among
atients with AF, which has implications for the ultimate
ole of these agents in clinical practice.
Fourth, it is important to note that only 1 of the 4
miodarone trials and none of the dronedarone trials en-
olled patients with highly symptomatic AF. However,
limination of symptoms due to AF is often the primary
eason to attempt to restore and maintain sinus rhythm in
atients with AF. Given that only 1 of the 8 trials included
n this indirect meta-analysis explicitly enrolled symptom-
tic patients in their study inclusion criteria, we need to
uestion whether the indications for chronic antiarrhythmic
herapy in the patients evaluated in this meta-analysis are
elevant to contemporary practice.
Finally, this meta-analysis was unable to evaluate the
ole of amiodarone or dronedarone on quality of life.
revious studies (17,18) have not shown that a rhythm
ontrol strategy using an antiarrhythmic drug improves
uality of life in patients with stable symptoms. However,
inus rhythm may not have been maintained in a majority
f patients in these studies. This finding is particularly
mportant when considering that patients with symptom-
tic AF are primarily interested in treatments that will
mprove their health status and reduce symptom burden.
adiofrequency catheter ablation therapy has been shown
o markedly improve quality of life and left ventricular
unction in patients with symptomatic AF by achieving
reater rates of sinus rhythm maintenance (2,3). Should
ngoing clinical trials of ablation therapy also demon-
trate reductions in rates of stroke or death, the role of
hronic antiarrhythmic therapy in treating AF would
ave to be reassessed in comparison to nonpharmacologic
herapy (19).
In summary, although this study by Piccini et al. (13)
oes raise provocative questions regarding the effectiveness
nd safety of dronedarone versus amiodarone, the results are
ypothesis generating and require confirmation from di-
ect comparisons in adequately powered clinical trials. In
he meantime, clinicians will need to balance whether the
se of dronedarone, a less efficacious but possibly safer
ntiarrhythmic drug than amiodarone (in patients with-
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ients with AF.
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merica Heart Institute, 5th Floor, 4401 Wornall Road, Kansas
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